HOB Biotech Financials
| 688656 Stock | 111.45 1.35 1.23% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 59.4 M | 55.2 M |
|
|
HOB | Select Account or Indicator |
Understanding current and past HOB Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of HOB Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in HOB Biotech's assets may result in an increase in income on the income statement.
Please note, the presentation of HOB Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, HOB Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of HOB Biotech's management manipulating its earnings.
HOB Biotech Stock Summary
HOB Biotech competes with Industrial, Kweichow Moutai, Agricultural Bank, China Mobile, and China Construction. HOB Biotech is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| ISIN | CNE100004C37 |
| Business Address | Building C6 and |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.hobiotech.com |
| Phone | 86 512 6956 1996 |
You should never invest in HOB Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of HOB Stock, because this is throwing your money away. Analyzing the key information contained in HOB Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
HOB Biotech Key Financial Ratios
HOB Biotech's financial ratios allow both analysts and investors to convert raw data from HOB Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of HOB Biotech over time and compare it to other companies across industries.| Revenue | 394.41 M | ||||
| Gross Profit | 320.16 M | ||||
| EBITDA | 78.62 M | ||||
| Net Income | 47.92 M | ||||
| Total Asset | 949.26 M |
HOB Biotech Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 283.2M | 296.4M | 863.9M | 944.6M | 949.3M | 526.8M | |
| Other Current Liab | 72.0M | 35.7M | 49.5M | 48.7M | 3.1M | 3.0M | |
| Net Debt | (40.7M) | (14.8M) | (419.0M) | (88.4M) | (79.5M) | (83.5M) | |
| Retained Earnings | 23.1M | 72.9M | 131.3M | 133.9M | 162.1M | 170.2M | |
| Accounts Payable | 5.9M | 7.5M | 11.1M | 48.3M | 23.9M | 15.2M | |
| Cash | 90.8M | 58.8M | 449.9M | 153.8M | 163.5M | 138.9M | |
| Inventory | 59.6M | 61.9M | 68.2M | 87.8M | 111.2M | 69.7M | |
| Other Current Assets | 2.2M | 1.3M | 3.0M | 3.9M | 959.4K | 911.4K | |
| Total Liab | 133.5M | 90.0M | 93.9M | 165.0M | 138.5M | 116.4M | |
| Total Current Assets | 176.5M | 158.7M | 570.0M | 423.0M | 328.2M | 263.7M | |
| Short Term Debt | 45.0M | 20.0M | 25.5M | 55.7M | 64.0M | 34.4M | |
| Intangible Assets | 11.7M | 11.3M | 12.2M | 12.6M | 11.9M | 8.4M |
HOB Biotech Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 1.3M | 1.9M | 1.2M | 1.9M | 2.5M | 1.9M | |
| Total Revenue | 259.1M | 221.9M | 317.7M | 320.4M | 394.4M | 271.3M | |
| Gross Profit | 176.4M | 145.5M | 219.2M | 202.3M | 245.0M | 179.6M | |
| Operating Income | 70.1M | 65.1M | 97.5M | 47.6M | 55.2M | 59.4M | |
| Ebit | 70.1M | 65.1M | 97.5M | 47.6M | 54.7M | 56.7M | |
| Research Development | 25.4M | 24.1M | 31.8M | 38.7M | 47.0M | 32.2M | |
| Ebitda | 88.3M | 82.8M | 125.2M | 80.8M | 92.9M | 75.5M | |
| Cost Of Revenue | 82.7M | 76.4M | 98.5M | 118.1M | 149.4M | 91.7M | |
| Income Before Tax | 73.6M | 65.1M | 99.1M | 46.5M | 56.6M | 57.3M | |
| Net Income | 63.8M | 56.6M | 86.2M | 41.7M | 47.3M | 49.7M | |
| Income Tax Expense | 9.7M | 8.5M | 12.9M | 4.8M | 5.6M | 7.2M |
HOB Biotech Key Cash Accounts
Cash flow analysis captures how much money flows into and out of HOB Biotech Group. It measures of how well HOB is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money HOB Biotech brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money HOB had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what HOB Biotech has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (10.5M) | (2.3M) | (6.3M) | (19.6M) | (23.4M) | (22.2M) | |
| Change In Cash | 24.2M | (31.9M) | 391.0M | (296.6M) | 10.2M | 14.9M | |
| Free Cash Flow | 33.8M | 1.2M | (63.1M) | (161.9M) | (75.3M) | (71.6M) | |
| Change In Working Capital | (10.7M) | (2.8M) | 2.5M | (18.8M) | 3.8M | 4.0M | |
| Begin Period Cash Flow | 66.5M | 90.8M | 58.8M | 449.9M | 153.3M | 118.3M | |
| Other Cashflows From Financing Activities | 55M | 60M | 504.8M | 43.8M | 50.4M | 47.9M | |
| Depreciation | 13.3M | 15.4M | 24.5M | 32.5M | 39.5M | 20.3M | |
| Other Non Cash Items | 2.1M | (11.0M) | (8.4M) | 2.9M | 10.5M | 11.0M | |
| Dividends Paid | 41.5M | 49.2M | 19.8M | 34.7M | 20.8M | 23.5M | |
| Capital Expenditures | 34.8M | 57.0M | 167.9M | 220.2M | 178.0M | 99.4M | |
| Total Cash From Operating Activities | 68.6M | 58.2M | 104.8M | 58.3M | 102.7M | 64.3M | |
| Net Income | 63.8M | 56.6M | 86.2M | 41.7M | 47.9M | 49.8M | |
| Total Cash From Financing Activities | (10.5M) | (55.3M) | 441.0M | (10.9M) | (12.5M) | (11.9M) | |
| End Period Cash Flow | 90.8M | 58.8M | 449.9M | 153.3M | 163.5M | 138.8M |
HOB Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HOB Biotech's current stock value. Our valuation model uses many indicators to compare HOB Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HOB Biotech competition to find correlations between indicators driving HOB Biotech's intrinsic value. More Info.HOB Biotech Group is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.61 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for HOB Biotech Group is roughly 1.65 . Comparative valuation analysis is a catch-all model that can be used if you cannot value HOB Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for HOB Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.HOB Biotech Group Systematic Risk
HOB Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. HOB Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-two with a total number of output elements of nineteen. The Beta measures systematic risk based on how returns on HOB Biotech Group correlated with the market. If Beta is less than 0 HOB Biotech generally moves in the opposite direction as compared to the market. If HOB Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one HOB Biotech Group is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of HOB Biotech is generally in the same direction as the market. If Beta > 1 HOB Biotech moves generally in the same direction as, but more than the movement of the benchmark.
HOB Biotech Group Total Assets Over Time
HOB Biotech Thematic Clasifications
HOB Biotech Group is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
HOB Biotech December 13, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of HOB Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of HOB Biotech Group. We use our internally-developed statistical techniques to arrive at the intrinsic value of HOB Biotech Group based on widely used predictive technical indicators. In general, we focus on analyzing HOB Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build HOB Biotech's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.77 | |||
| Information Ratio | 0.33 | |||
| Maximum Drawdown | 32.81 | |||
| Value At Risk | (6.47) | |||
| Potential Upside | 20.0 |
Complementary Tools for HOB Stock analysis
When running HOB Biotech's price analysis, check to measure HOB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HOB Biotech is operating at the current time. Most of HOB Biotech's value examination focuses on studying past and present price action to predict the probability of HOB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HOB Biotech's price. Additionally, you may evaluate how the addition of HOB Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |